Cargando…

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia

An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly deregulated in many types of cancer. Nevertheless, the effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alameen, Ayman A.M., Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Ultimo, Simona, McCubrey, James A., Gonelli, Arianna, Marisi, Giorgia, Ulivi, Paola, Capitani, Silvano, Neri, Luca M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342446/ https://www.ncbi.nlm.nih.gov/pubmed/27494886 http://dx.doi.org/10.18632/oncotarget.10984

Ejemplares similares

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
por: Simioni, Carolina, et al.
Publicado: (2015)

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
por: Ultimo, Simona, et al.
Publicado: (2017)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases
por: Ultimo, Simona, et al.
Publicado: (2018)

Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise
por: Ultimo, Simona, et al.
Publicado: (2018)

Impact of physical exercise in cancer survivors during and after antineoplastic treatments
por: Ferioli, Martina, et al.
Publicado: (2018)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments
por: Simioni, Carolina, et al.
Publicado: (2018)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging
por: Simioni, Carolina, et al.
Publicado: (2018)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
por: Basile, Maria Sofia, et al.
Publicado: (2022)

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis
por: Mammana, Santa, et al.
Publicado: (2018)

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response
por: Martelli, Alberto M., et al.
Publicado: (2019)

The role of the mTOR pathway in diabetic retinopathy
por: Casciano, Fabio, et al.
Publicado: (2022)

Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Martelli, Alberto M., et al.
Publicado: (2023)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Clinical perspectives of TRAIL: insights into central nervous system disorders
por: Tisato, Veronica, et al.
Publicado: (2016)

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
por: Tisato, Veronica, et al.
Publicado: (2017)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
por: Taylor, Jackson R., et al.
Publicado: (2011)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v85ga7jn37jctlfp4m83ra4vlp